This profile is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any compound.
What Is BPC-157?
BPC-157, short for Body Protection Compound-157, is a synthetic pentadecapeptide composed of 15 amino acids. It is derived from a portion of the body protection compound found naturally in human gastric juice, where it appears to play a role in protecting and maintaining the integrity of the gastrointestinal tract. The peptide was first isolated and characterized by researchers at the University of Zagreb, and has since accumulated an impressive body of preclinical data across a remarkably wide range of tissue types.
What distinguishes BPC-157 from many other research peptides is the breadth of its studied effects. While most healing compounds operate within a narrow tissue domain, BPC-157 has been studied for its regenerative effects on tendons, ligaments, muscles, bone, peripheral nerves, the gut epithelium, and even the central nervous system. This systemic versatility â combined with an excellent preclinical safety profile â has made it the most commonly discussed peptide in biohacking and self-optimization communities worldwide.
BPC-157 is classified as a research chemical in most jurisdictions and is not approved for human use by the FDA or equivalent regulatory agencies. However, it is not a scheduled or controlled substance in the United States, and is widely available as a research peptide. It can be administered subcutaneously (via injection) for systemic or local effects, or taken orally, where it appears to retain bioactivity particularly for gastrointestinal conditions due to its partial resistance to gastric degradation.
How It Works
BPC-157 operates through multiple simultaneous molecular pathways, which likely explains its diverse range of studied effects. One of its primary mechanisms involves the upregulation of growth hormone receptor expression in tendon fibroblasts, enhancing these cells' sensitivity to endogenous growth hormone signals and accelerating the repair cascade. Concurrently, BPC-157 stimulates nitric oxide (NO) synthesis through activation of endothelial nitric oxide synthase (eNOS), which dilates blood vessels, improves oxygen delivery to injured tissue, and supports the formation of new blood vessels (angiogenesis) â a critical requirement for tissue repair.
At the cellular level, BPC-157 activates the FAK-paxillin pathway, which governs the migration and proliferation of tendon fibroblasts and other tissue-repair cells. This pathway is essential for cells to physically move into and colonize damaged tissue areas. BPC-157 also modulates the expression of numerous growth factors including VEGF, EGF, and FGF, collectively promoting an environment that favors regeneration over scarring. In gut tissue specifically, it strengthens tight junction proteins and the intestinal epithelial barrier, reduces pro-inflammatory cytokine signaling, and has been shown in animal models to completely heal perforated bowel, intestinal fistulas, and drug-induced gut damage.
BPC-157's interaction with the dopaminergic and serotonergic systems in the CNS is also an active area of research, with studies suggesting it can counteract the neurotoxic effects of certain drugs and reduce the behavioral consequences of neurological damage â mechanisms not shared by most peripheral healing peptides.
Key Benefits Discussed in Research
Dosing Reference (Educational Only)
All dosing information is derived from preclinical research and anecdotal community experience. Work with a qualified physician before starting any protocol.
| Parameter | Common Research Range | Notes |
|---|---|---|
| SubQ Dose | 250â500 mcg/day | Injected near site of injury for local effect, or abdomen for systemic use |
| Oral Dose | 500â1,000 mcg/day | Higher dose needed due to partial GI degradation; more appropriate for gut-specific goals |
| Cycle Length | 4â12 weeks | Most users report noticeable effects within 2â4 weeks for acute injuries |
| Frequency | Once daily | Some protocols split into AM/PM dosing for severe injury |
| Reconstitution | Bacteriostatic water | Typically 2ml per 5mg vial; refrigerate after reconstitution |
| Storage (lyophilized) | Room temp up to 3 months | Refrigerate for longer storage; reconstituted solution stable ~30 days refrigerated |
Want the Full BPC-157 Protocol?
Join SDBioHack and access community-validated protocols, sourcing checklists, and expert Q&A.
Side Effects & Safety Profile
BPC-157 has one of the most favorable preclinical safety profiles of any research peptide studied to date. Animal studies have used doses far exceeding typical human-equivalent amounts without detecting toxicity, organ damage, or significant adverse events. Unlike many healing peptides, BPC-157 does not appear to alter normal hormone levels, suppress the hypothalamic-pituitary axis, or cause dependency. The absence of human clinical trial data is an important caveat â the safety profile is based on animal research and extensive anecdotal reports from the biohacking community.
The most commonly reported side effects in human self-experimentation are mild: nausea or GI discomfort when taken on an empty stomach (particularly oral dosing), lightheadedness on the first few injections, and localized redness or minor irritation at the injection site. These effects typically resolve quickly. There are no widely reported cases of serious adverse events attributable specifically to BPC-157 in the published or community literature.
- Individuals with a history of cancer should exercise caution â BPC-157 promotes angiogenesis and cell proliferation, which are theoretically relevant to tumor environments.
- Pregnancy and breastfeeding: insufficient data; avoid use.
- Do not use if allergic to any component of the peptide or its excipients.
- Ensure peptide is sourced from a reputable supplier with third-party purity testing to avoid contamination-related adverse effects.
Common Stacks & Pairings
BPC-157 is frequently combined with other peptides and compounds to amplify its healing effects. The most discussed pairing is with TB-500 (Thymosin Beta-4), which has become known as the "gold standard" healing stack in the biohacking community. While BPC-157 tends to act locally at the site of injury, TB-500 provides more systemic tissue repair signaling, making the combination theoretically complementary. Other common pairings include GHK-Cu for enhanced collagen synthesis and skin repair, and Ipamorelin (a growth hormone secretagogue) to layer anabolic signaling on top of BPC-157's repair mechanisms.
Frequently Asked Questions
BPC-157 occupies a regulatory gray area in most countries. In the United States, it is not a scheduled or controlled substance, meaning it is not illegal to possess. However, it is not FDA-approved for human use and cannot be legally marketed for human consumption. It is sold legally as a "research chemical" for laboratory research purposes. The legal status varies by country â some nations have stricter regulations. Always verify local laws before purchasing.
Injectable (subcutaneous) BPC-157 provides more reliable systemic bioavailability and is generally preferred when targeting tendons, ligaments, muscles, or nerves outside the GI tract. Injecting near the site of injury is common practice for localized healing. Oral BPC-157 undergoes partial degradation in the stomach but retains enough bioactivity to exert direct effects on the GI mucosal lining â making it potentially more appropriate for gut healing goals (ulcers, leaky gut, IBD). For systemic effects, injectable remains the gold standard.
This varies considerably by indication and individual. Anecdotally, users with acute injuries (recent tendon strain, muscle tear) often report noticeable improvements in pain and function within 1â2 weeks. Chronic injuries or degenerative conditions may take 4â8 weeks to show meaningful progress. Gut healing effects for conditions like gastric ulcers appear faster in animal research (days to a couple of weeks). There is significant individual variability based on injury severity, age, baseline health, and dosing precision.
BPC-157 has a robust body of animal research specifically addressing GI conditions. It has been shown to heal gastric ulcers, intestinal fistulas, colitis, and short bowel syndrome in rodent models, largely through its stabilization of the gut mucosal barrier and its anti-inflammatory effects on intestinal epithelial cells. Oral administration is often preferred for gut-targeted protocols as it delivers the peptide directly to the mucosal surface. Some practitioners also stack BPC-157 with KPV or Larazotide for comprehensive gut barrier support. Human clinical data remains limited, so outcomes cannot be guaranteed.
Lyophilized (freeze-dried powder) BPC-157 is relatively stable at room temperature for up to 3 months when kept away from heat and light. For longer storage, refrigeration is recommended. Once reconstituted with bacteriostatic water, the solution should always be refrigerated and used within approximately 30 days. Avoid freeze-thaw cycles of reconstituted solution, and protect from direct sunlight at all times.
Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology. 2016;14(8):857â865.
Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774â780.
Seiwerth S, et al. "BPC 157's Effect on Healing." Journal of Physiology (Paris). 1997;91(3â5):173â178.
Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor. 2010;16(3):BR81â88.
Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design. 2013;19(1):76â83.